We are founded with the sole purpose of streamlining the way we diagnose diseases

About Us

At ALiA BioTech (formerly known as Sanwa BioTech in operation), we deliver accurate and actionable diagnostic information through our Point-Of-Care Testing (POCT) platform and BioChip, for faster clinical decisions and better economic outcomes.

This streamlined platform is designed to be employed in human healthcare, pet health, livestock surveillance and food safety for disease detection and monitoring, especially at the human-animal interface (HAI) to combat infectious disease outbreaks.

Our Vision & Value

Since our establishment in December 2012, we intend to become a driving force of disease diagnostics and revolute healthcare solutions into the future, which is originated from a strong vision for transforming the diagnostic landscape with faster response to disease management.

In order to accomplish our vision, we have developed ALiA®, an end-to-end Point-of-Care Testing (POCT) platform with digital healthcare management solutions for combating time-critical and life-threatening diseases and outbreaks.

ISO Certification

We are ISO 13485:2016 certified medical device manufacturer since 2018.

ISO 13485:2016 is an internationally recognized quality management system standard for medical device manufacturers. ISO13485 ensures product reliability, regulatory compliance and quality management throughout the life cycle of medical devices, i.e. from product conception to placing the device onto the market, to obsolescence of the device. ISO13485 compliance is a prerequisite for a large number of jurisdictions to place medical devices on the market.

Our Roadmap

2012
Founded
Sanwa BioTech Founded

We are founded as a Hong Kong base's biotech startup company

2013
R&D
Science Park Research Lab Established

Innovation &  Technology Support Program & the first biotech fund in HK

2016
R&D
Headquarters established
Headquarter at Fotan and WOFE at Shenzhen established respectively
2017
R&D
ALiA®

ALiA® prototype 2.5 launched

2018
R&D
Ariel™

ISO 13485:2016 certified

Soft launch of Ariel™ 2.2

2019
R&D
Certificates

ALiA® CE Accredited

HK clinical trial IRB approved

2020
Fast Development
Development

Lab capacity expansion at Fo Tan

HKU COVID-19 clinical study

Respiratory Infections Pipelines product launch

FED EUDA & CE IVDD  NMPA(CFDA) certified

2021
Production
Increase of production capability

Fo Tan capacity expansion of BioChips and devices

2022
Rebranding
Rebranded as ALiA BioTech

Sanwa BioTech is rebranded as ALiA BioTech

2022
Expansions
AMC Program

AMC program kick-off in TKO HK

2023
Production
AMC starts operation

Capacity scale-up to 30M BioChips and 20,000 devices